ERBB2 and non-small cell lung carcinoma: In advanced NSCLC with positive PD-L1 expression, TP53 has the highest mutation frequency at 78% (62/80), followed by EGFR, KRAS, and ERBB2 with higher mutation frequencies at 21% (17/80), 19% (15/80), and 12% (10/80), respectively (Fig. 2).